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Abstract
 
There is evidence that the classical complement pathway may be activated via a “C1-tickover”
mechanism, analogous to the C3-tickover of the alternative pathway. We have quantitated and
characterized this pathway of complement activation. Analysis of freshly collected mouse and
human plasma revealed that spontaneous C3 activation rapidly occurred with the generation of
C3 fragments in the plasma. By the use of complement- and Ig-deficient mice it was found that
C1q, C4, C2, and plasma Ig were all required for this spontaneous C3 activation, with the al-
ternative complement pathway further amplifying C3 fragment generation. Study of plasma
from a human with C1q deficiency before and after therapeutic C1q infusion confirmed the
existence of a similar pathway for complement activation in humans. Elevated levels of plasma
C3 were detected in mice deficient in complement components required for activation of ei-
ther the classical or alternative complement pathways, supporting the hypothesis that there is
continuous complement activation and C3 consumption through both these pathways in vivo.
Blood stasis was found to stimulate C3 activation by classical pathway tick-over. This antigen-
independent mechanism for classical pathway activation may augment activation of the com-
plement system at sites of inflammation and infarction.
Key words: innate immunity • alternative complement pathway • C3 tick-over • 
inﬂammation • deﬁciency
 
Introduction
 
The complement system consists of 
 
 
 
30 proteins that con-
tribute to many aspects of inflammation and host defense,
including opsonization of foreign particles, cell lysis, and
regulation of cellular immune responses.
There are three pathways by which effector functions of
complement can be activated, namely the classical, man-
nose-binding lectin, and alternative pathways. The alterna-
tive pathway is distinct from the other two pathways in that
specific pathogen recognition is not required for activation.
Rather, it is in a state of continuous low-level activation as
a result of spontaneous hydrolysis of the thioester group in
native C3 (1, 2). This spontaneous “C3 tick-over” leads to
C3b deposition on biological particles in plasma or on cell
surfaces (1, 3, 4). Host cell surfaces are protected from sub-
sequent complement activation mediated by the deposited
C3b by the presence of a number of membrane-associated
inhibitors (5). In contrast, foreign cells lack these inhibitory
molecules resulting in complement activation and amplifi-
cation via the alternative pathway.
The classical and mannose-binding lectin pathways share
a number of proteins and employ homologous activating
complexes that recognize specific pathogen molecules to
induce complement activation. Ig bound to antigen acti-
vates the classical pathway through the binding of C1q
which then activate C1r and C1s. Of the Ig classes antigen-
complexed IgM and IgG efficiently bind complement and
are the primary mediators of activation via the classical
pathway. Among the IgG subclasses in humans, IgG3 and
IgG1 bind and activate C1 readily, whereas IgG2 does so
poorly, and IgG4 exhibits no activity (6–8). In the mouse,
IgG2a, IgG2b, and IgG3 all efficiently activate C1, whereas
IgG1, the murine homologue of human IgG4, is a very
poor activator (7, 9–11). On the other hand, induction of
the mannose-binding lectin pathway is mediated by recog-
nition of arrays of terminal mannose groups on pathogens
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by mannose-binding lectin (MBL)
 
*
 
 (12, 13). MBL is a
C-type lectin (14), structurally similar to C1q which, on
binding its ligand, activates two serine proteases, MBL-
associated serine protease-1 (MASP-1) (15, 16) and MASP-2
(17, 18), which in turn activate the classical pathway com-
plement proteins C4 and C2.
Consumption of complement with activation of C3 is
known to occur ex vivo in blood from most species. For
example, mouse complement is considered labile and weak
as clotting mouse blood at room temperature leads to sub-
stantial losses in hemolytic complement activity (19), and
cleavage of C3 (10). However, despite the widespread
knowledge that C3 activation occurs in blood ex vivo, the
molecular basis of this spontaneous activation of comple-
ment has not been delineated.
In this paper we demonstrate that continuous activation
of complement occurs via the classical pathway in the
blood and plasma of mice and humans both in vitro and in
vivo. Activation of complement appears to be mediated by
soluble Ig, largely IgG, and results in the generation of C3
fragments in the plasma.
 
Materials and Methods
 
Mice.
 
C57BL/6 and recombinase-activating gene 2–deficient
mice (RAG
 
 
 
/
 
 
 
) on a C57BL/6 background were used between
6–20 wk old and were housed under specific pathogen-free con-
ditions at the John Curtin School of Medical Research (JCSMR).
C1q-knockout (C1qa
 
 
 
/
 
 
 
) (20), C4
 
 
 
/
 
 
 
 (21, 22), factor B knock-
out (Bf
 
 
 
/
 
 
 
), and H2-Bf,C2
 
 
 
/
 
 
 
 mice (23) were all generated as
previously described. Mice were bred onto a C57BL/6 back-
ground and maintained under specific pathogen-free conditions
at the Biological Services Unit, Hammersmith Hospital, London.
At the time of their use the mice were 8–12 wk old. All animal
experiments reported in this paper were approved by the Austra-
lian National University Animal Experimentation Ethics Com-
mittee, and experiments performed at Hammersmith Hospital
were carried out according to institutional guidelines.
 
Blood and Plasma Isolation.
 
C57BL/6, RAG
 
 
 
/
 
 
 
, C4
 
 
 
/
 
 
 
, Bf
 
 
 
/
 
 
 
,
H2-Bf,C2
 
 
 
/
 
 
 
, and C1qa
 
 
 
/
 
 
 
 mice were exsanguinated from the
chest cavity immediately after death of the mice by CO
 
2
 
 adminis-
tration. The blood was collected directly into the anticoagulant
heparin (5 U/ml) or hirudin (50 U/ml) and used in experiments
ex vivo. Plasma was then isolated from the blood by centrifuga-
tion (800 
 
g
 
, 5 min, 4
 
 
 
C) to remove cells, and stored at 4
 
 
 
C until
use. All mouse plasma was used within 2 h of collection.
Blood was collected from normal and C1q-deficient humans
into heparin (5 U/ml), hirudin (50 U/ml), or heparin and 2 mM
EDTA, pH 8.0. Plasma was then isolated from the blood by cen-
trifugation (800 
 
g
 
, 5 min, 4
 
 
 
C) to remove cells, and either stored
at 4
 
 
 
C or in frozen aliquots (
 
 
 
70
 
 
 
C) until use. Blood was also
collected, as above, from a C1q-deficient patient immediately af-
ter the therapeutic intravenous infusion of 400 ml of Octaplas
(solvent/detergent treated human plasma; Octapharma Ltd.), and
the plasma stored at 
 
 
 
70
 
 
 
C until use.
 
Cell Preparation.
 
Spleen cell suspensions were prepared from
C57BL/6 mice by gentle dissociation of the spleen between two
 
frosted slides into PBS/0.1% BSA, followed by uptake of the cell
suspension once into a syringe through a 26 g needle. Cells were
then pelleted (500 
 
g
 
, 5 min), before resuspension in Tris/NH
 
4
 
Cl
(17 mM Tris, 140 mM NH
 
4
 
Cl, pH 7.2) to lyse erythrocytes. The
cell suspension was then incubated at room temperature for 5
min before washing the cells twice in PBS/0.1% BSA (500 
 
g
 
, 5
min), and finally the cells were resuspended in PBS/0.1% BSA at
2.5 
 
 
 
 10
 
6
 
 cells per ml and stored on ice.
Raji cells were provided by Hilary Warren (Canberra Hospi-
tal, Canberra, Australia) and cultured in RPMI 1640 supple-
mented with 10% FCS and antibiotics (120 mg/liter penicillin;
200 mg/liter streptomycin; and 200 mg/liter neomycin). For the
in vitro complement assays the Raji cells were harvested and re-
suspended in PBS/0.1% BSA at 2.5 
 
  
 
10
 
6
 
 cells per ml and stored
on ice until use.
 
Ex Vivo Assay of Complement Activation.
 
In some experi-
ments, after collection into heparin (5 U/ml) or hirudin (50
U/ml) to prevent blood clotting, the blood was immediately ali-
quoted into 100-
 
 
 
l volumes and incubated at 37
 
 
 
C for up to 60
min. At different time points tubes were removed from the water
bath, 2 ml of 500 mM EDTA, pH 8.0, added (10 mM final con-
centration), and the samples placed on ice. To induce immune
complex (IC) formation 20 mg/ml rabbit anti–mouse Ig (Dako)
was added to blood aliquots before incubation. Control blood
was collected directly into EDTA (10 mM). Blood samples were
then centrifuged (800 
 
g
 
, 5 min) to collect the plasma.
Complement activity was restored in frozen EDTA-containing
human plasma samples (i.e., plasma containing 5 U/ml heparin, 2
mM EDTA) by the addition of exogenous Ca
 
2
 
 
 
 (3 mM final
concentration). Aliquots of the recalcified plasma were then incu-
bated for 0, 5, 15, or 30 min at 37
 
 
 
C before the addition of 10
mM EDTA. Variations of this basic assay involved the addition of
exogenous purified human C1q (20 
 
 
 
g/ml final concentration;
Sigma-Aldrich) or Octaplas (final C1q concentration 
 
 
 
20 
 
 
 
g/ml;
Octapharma Ltd.) to recalcified plasma before incubation at 37
 
 
 
C.
 
Immunofluorescence Flow Cytometry for Plasma C3 Fragments.
 
Individual plasma samples (20 
 
 
 
l) were added to either 5 
 
  
 
10
 
4
 
splenic lymphocytes (for mouse plasma) or 5 
 
  
 
10
 
4
 
 Raji cells (for
human plasma) in 96-well v-bottomed plates (Costar) and incu-
bated on ice for 30 min. Plates were then washed three times
with PBS/0.1% BSA (300 
 
g
 
, 2 min, 4
 
 
 
C) before incubating the
cells for 30 min on ice with C3-specific antibodies. In the case of
mouse plasma samples, the splenic lymphocytes were incubated
with a polyclonal goat anti–mouse C3-FITC antibody (Cappel;
ICN Pharmaceuticals), with the splenic B cells being identified by
a monoclonal anti–mouse B220-PE antibody (BD PharMingen).
For human plasma samples, Raji cells were incubated with either
a polyclonal goat anti–human C3-FITC antibody (Cappel; ICN
Pharmaceuticals) or a polyclonal rabbit anti–human C3d-FITC
antibody (Dako). Cells were finally washed three times with PBS/
0.1% BSA (300 
 
g
 
, 2 min, 4
 
 
 
C) before performing two-color flow
cytometry using a FACS
 
®
 
 (Becton Dickinson). Data from 2 
 
 
 
10
 
4
 
 cells were analyzed using WinMDI software (Joseph Trotter,
Scripps Research Institute, La Jolla, CA). In the case of mouse
splenocytes, samples were analyzed by first gating on lympho-
cytes, based on forward and side scatter, followed by gating for
B220
 
 
 
 B cells. The relative amount of C3 fragments on the
membrane of mouse B220
 
 
 
 B cells or Raji cells was assessed on
the basis of mean fluorescence intensity (MFI), in arbitrary units.
 
Immunoprecipitation and Western Blotting for Plasma C3.
 
Mouse
plasma from ex vivo incubation experiments was diluted 1/250
in PBS (2 
 
 
 
l plasma per 500 
 
 
 
l PBS) in Eppendorf tubes and
added to 10 ml of CNBr-activated Sepharose beads (Amersham
 
*
 
Abbreviations used in this paper:
 
 HRG, histidine-rich glycoprotein; IC, im-
mune complex; MBL, mannose-binding lectin; MFI, mean fluorescence
intensity; RAG, recombinase-activating gene. 
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Pharmacia Biotech) that had been conjugated with a polyclonal
goat anti–mouse C3 antibody. The bead-plasma mixture was in-
cubated at 4
 
 
 
C on a rotating wheel for 60 min, before washing of
the beads three times with PBS (50 
 
g
 
, 20 s) to remove unbound
plasma protein. The beads were then resuspended in 50 
 
 
 
l of re-
duced SDS-PAGE sample buffer, and boiled for 5 min to dis-
lodge bound C3 fragments. C3 fragments were resolved on a
10% SDS-PAGE gel (Gradipore), transferred to a nitrocellulose
filter (Bio-Rad Laboratories), and the filter was probed with a bi-
otin-conjugated polyclonal goat anti–mouse C3 antibody fol-
lowed by streptavidin-horseradish peroxidase (HRP; Amersham
Pharmacia Biotech). Finally, bands were revealed by enhanced
chemiluminescence (ECL; Amersham Pharmacia Biotech).
 
Complement Activation in RAG
 
 
 
/
 
 
 
 Mouse Plasma Reconstituted
with Ig.
 
The following antibodies were used for reconstitution
experiments. Mouse myelomas of the following Ig classes and
subclasses: IgG1 (MOPC-31c); IgG2a
 
 
 
 (UPC-10); IgG2a
 
 
 
(HOPC-1); IgG2b (MOPC-141); IgG3 (FLOPC-21); IgM
(TEPC 183); and IgA (TEPC 15), and mouse mAbs specific for
human CD54 (IgG1, HA58), human CD158b (IgG2a
 
 
 
, DX27),
and rat 
 
 
 
/
 
 
 
-TCR (IgG1, RT3). All these antibodies were pur-
chased from Sigma-Aldrich. An IgG1 mAb specific for human
CD32 (clone 8.7) (24), both as the whole IgG1 molecule and as a
F(ab
 
 
 
)
 
2 
 
fragment was a kind donation from M. Hulett (John Cur-
tin School of Medical Research). An IgG1 mouse mAb specific
for human CD94 (WV2), and IgM mAbs specific for human
CD94 (WV4), CD56 (WV5), and CD57 (WV7) were donated
by H. Warren, Canberra Hospital, Canberra, Australia.
Blood was collected directly into the anticoagulant heparin (5
U/ml) and then 100-
 
 
 
l volumes were aliquoted into Eppendorf
tubes containing the different purified Igs (50 
 
 
 
g/ml final con-
centration), as listed above. Control tubes contained PBS instead
of the purified Igs, or EDTA to give a final concentration of 10
mM. All tubes were then incubated at 37°C for 10 min before ad-
dition of EDTA (10 mM final concentration). Tubes were finally
centrifuged (800 
 
g
 
, 5 min) to separate the plasma, the plasma col-
lected, and the amount of C3 fragments in the plasma determined
by immunofluorescence flow cytometry (described previously).
 
Complement Activation in a Vascular Stasis Model.
 
Mice were
injected intraperitoneally with 100 
 
 
 
l of heparin (20 U) in saline
and 10 min later killed by CO
 
2
 
 administration. Immediately or at
various time points after CO
 
2
 
 administration the mice were ex-
sanguinated from the chest cavity and the blood collected directly
into EDTA (20 mM final concentration). Plasma was then sepa-
rated by centrifugation (800 
 
g
 
, 5 min) and the level of C3 frag-
ments in the plasma determined by immunofluorescence flow cy-
tometry (described previously).
 
Complement Levels in Mouse and Human Plasma.
 
C3 levels in
mouse plasma were measured by rocket immuno-electrophoresis
as described previously (25). Samples were electrophoresed for
20 h at 15
 
 
 
C in a 1% agarose L gel (Amersham Pharmacia Bio-
tech) containing 3% polyclonal goat anti–mouse C3 antibody
(Cappel; ICN Pharmaceuticals) in 0.07 M barbiturate buffer, pH
8.8. Acute phase mouse sera containing a known amount of C3
were used as a standard.
Human plasma C3 and C4 levels were measured by radial im-
munodiffusion using sheep anti–mouse C3 and sheep anti–mouse
C4 antibodies (The Binding Site). Normal human sera containing
known amounts of C3 and C4 were used as standards.
 
Statistical Analysis.
 
Data are shown as mean values 
 
 
 
 standard
deviation, unless otherwise stated. Student’s 
 
t
 
 test was used for
comparisons with differences considered significant when
 
 P 
 
 
 
0.05.
 
Results
 
C3 Fragments Accumulate to High Levels in Plasma Ex
Vivo.
 
In initial experiments it was noted that complement
activation, as measured by the generation of C3 fragments,
rapidly occurred in heparinized mouse and human plasma
incubated in vitro at 37
 
 
 
C. C3 fragments were detected by
two methods; first by the specific binding of C3 fragments
to complement receptor 1 and 2 (CR1/2) on mouse and
human B cells in vitro, as detected by immunofluorescence
flow cytometry (Fig. 1, A and C), and second by Western
blot detection of C3 fragments in mouse plasma (Fig. 1 B).
Fig. 1 A shows a histogram of the binding of C3 fragments
from mouse plasma incubated for 10 min ex vivo (open
histogram) to B cells, with the B cell population being
identified by B220 expression. Similarly, Fig. 1 C shows a
histogram of the binding of C3 fragments from human
plasma incubated for 30 min ex vivo (open histogram) to
Raji cells, with bound C3 fragments being detected using
antibodies specific for human C3 or the C3 fragment C3d.
The binding of the mouse C3 fragments to B cells was de-
pendent on complement receptors as blocking of CR1/2,
with the antibody 7E9, prevented binding of the fragments
(data not shown).
The presence of C3 fragments in mouse plasma was con-
firmed by Western blot analysis of the C3 molecule (Fig. 1
B). In Fig. 1 B, lane T
 
0
 
, plasma was collected directly into
10 mM EDTA to prevent any complement activation ex
vivo. Here, almost all of the C3 observed was in the native
state with intact 
 
 
 
 and 
 
 
 
 chains accompanied by only a low
level of the 40-kD C3 fragment, C3dg. In contrast, when
blood was incubated for 10 min at 37
 
 
 
C ex vivo before ad-
dition of EDTA (Fig. 1 B, lane T
 
10
 
), then a large increase
in the amount of C3dg fragments present was observed, a
finding consistent with the flow cytometry data depicted in
Fig. 1, A and C.
As heparin was used in most assays, any potential in-
volvement of heparin in spontaneous complement activa-
tion was investigated. Blood was collected from normal
C57BL/6 mice or normal humans into either heparin, or
an alternative anticoagulant, hirudin, which does not
modulate complement activity (26). Comparable levels of
C3 fragments were detected in human plasma collected in
heparin or hirudin, after incubation at 37
 
 
 
C for up to 30
min in vitro (data not shown). In contrast, comparison of
the mouse blood samples showed approximately a two-
fold greater level of spontaneous complement activation
and C3 fragment generation in the presence of hirudin,
compared with that observed in the presence of heparin
(Fig. 1 D), showing that, if anything, heparin slightly in-
hibited the spontaneous complement activation. As a fur-
ther control for any artefactual effects of the anticoagu-
lant, blood was collected from C57BL/6 mice in the
absence of heparin or any other anticoagulant, and after
incubation of the blood in vitro, C3 fragments were
shown to be present in the serum (data not shown). In ad-
dition, it is important to note that formation of the C3
fragments did not require the presence of RBCs or leuko- 
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cytes as it occurred in plasma in the absence of any cells
(data not shown).
We compared the amount of spontaneous C3 con-
sumption that occurred in blood ex vivo with that in-
duced by the presence of ICs. Blood was collected from
C57BL/6 mice into heparin (5 U/ml) to prevent clotting
in the absence or presence of 50 
 
 
 
g/ml of anti–mouse Ig
to induce IC formation, and then incubated at 37
 
 
 
C for 5
min before the addition of 10 mM EDTA. In the pres-
ence of IC a very high level of C3 fragments was gener-
ated (MFI 
 
 
 
 160) compared with those spontaneously
generated (MFI 
 
 
 
 6), demonstrating that spontaneous C3
consumption is slight compared with the level of activation
induced by ICs. No C3 fragments were generated in blood
from C1q-deficient mice even in the presence of ICs.
 
Spontaneous C3 Fragment Formation in Plasma Occurs via
the Classical Complement Pathway. To determine the com-
plement activation pathway responsible for the spontaneous
generation of C3 fragments ex vivo, the rate of formation
of C3 fragments in blood from normal C57BL/6 mice was
compared with that from C1qa / , C4 / , Bf / , H2-Bf,
C2 / , and RAG /  mice. Blood was collected from these
mice into heparin (5 U/ml) to prevent clotting, and then
incubated at 37 C for up to 15 min. At different time
points EDTA (10 mM) was added to stop complement ac-
tivity, and then the level of C3 fragments in the plasma of
these samples was measured by immunofluorescence flow
cytometry. By measuring the mean fluorescence of the B
cells for bound C3 the relative level of C3dg fragments in
the samples was quantified. Fig. 2 clearly shows that C3
fragments were rapidly generated in plasma from normal
C57BL/6 mice. In contrast, there was a complete absence
of C3 fragment generation in plasma from C1qa /  mice.
Table I summarizes the rate of formation of C3 fragments
Figure 1. Detection of C3 fragments in mouse and human blood following incubation ex vivo at 37 C. (A) The level of C3 fragments in mouse blood
collected directly into heparin and EDTA (T0) or collected into heparin and incubated at 37 C for 10 min before addition of EDTA (T10). The histo-
grams represent the amount of C3 fragments detected on B220  B cells following incubation of splenic lymphocytes with T0 plasma (filled histogram) or
T10 plasma (open histogram), as measured by immunofluorescence flow cytometry. (B) Western blot analysis of C3 fragments in mouse plasma, as col-
lected in A. C3 was immunoprecipitated from plasma samples with polyclonal anti–mouse C3 antibody conjugated Sepharose beads, and the Western
blot was probed with biotin-labeled polyclonal anti–mouse C3 Ab and developed using streptavidin-HRP. Position of intact C3  and C3  chains and
the C3dg fragments, that bind to CR1/2 on B cells (A), is indicated. (C) The level of C3 fragments in human blood collected directly into heparin and
EDTA (T0) or into heparin and incubated at 37 C for 30 min before addition of EDTA (T30). The histograms represent the amount of C3 (solid line) or
C3d (broken line) fragments detected on Raji cells after incubation with T0 plasma (filled histogram) or T30 plasma (open histograms), as measured by im-
munofluorescence flow cytometry. (D) The rate of formation of C3 fragments in blood from C57BL/6 mice collected into either heparin ( ) or hirudin
( ) is depicted, as measured by the binding of C3 fragments to B220  spleen cells using immunofluorescence flow cytometry, as shown in A. Error bars
represent   SD of means of triplicate assays.751 Manderson et al.
in blood from normal, complement component–deficient,
and Ig-deficient mice, and demonstrates a number of im-
portant points. First, no C3 fragment production was ob-
served in plasma from C1qa / , C4 / , and H2-Bf, C2 / 
mice demonstrating that spontaneous C3 fragment genera-
tion involves activation through the classical complement
pathway, and not the lectin or alternative pathways. How-
ever, in the absence of the alternative complement pathway
(Bf /  mice) a substantial reduction in the level of C3 frag-
ments was observed (54   26%), suggestive that this path-
way is involved in amplification of C3 fragment generation
initiated through the classical complement pathway. In ad-
dition, the major reduction of C3 fragment generation in
the plasma of RAG /  mice (16   2%) suggests an impor-
tant role for plasma Ig in complement activation.
To determine if the classical complement pathway is also
responsible for the spontaneous generation of C3 fragments
in human blood ex vivo, the rate of formation of C3 frag-
ments was compared in blood from normal and C1q-defi-
cient patients. Blood was initially collected from normal
and C1q-deficient humans directly into heparin (5 U/ml)
and 2 mM EDTA and the plasma frozen at  70 C until
use. The plasma samples were then recalcified by the addi-
tion of 3 mM Ca2 , and incubated for up to 30 min at
37 C. We have previously shown that this concentration of
Ca2  restored the spontaneous generation of C3 fragments
(data not shown). As a control for these experiments spon-
taneous complement activation was measured in freshly
collected heparinized blood from normal patients incubated
for 30 min at 37 C directly ex vivo and compared with
normal plasma collected in heparin and EDTA, frozen, and
recalcified with 3 mM Ca2  before incubation at 37 C.
Similar levels of spontaneous complement activation were
measured in both fresh and stored samples (data not shown).
Spontaneous complement activation and generation of
C3 fragments was absent in plasma from C1q-deficient pa-
tients (Fig. 3 A), as observed in C1qa /  mice. Addition of
20  g/ml of purified human C1q to the plasma from the
C1q-deficient patients, previously shown to restore  80%
classical complement pathway activity (data not shown), re-
sulted in the restoration of the ability of the plasma to
spontaneously generate C3 fragments to well above that of
plasma from normal donors (Fig. 3 A). As controls, exoge-
nous purified C1q was added to plasma from normal hu-
mans and did not enhance the level of C3 fragments gener-
ated. The plasma from C1q-deficient patients did not
contain any detectable levels of anti-C1q antibodies (data
not shown). In addition, blood was collected from a C1q-
deficient patient who receives regular therapeutic infusions
of Octaplas to temporarily replenish the plasma C1q levels
(plasma C1q levels  20  g/ml after infusion). In plasma
collected from this C1q-deficient patient, immediately after
the infusion of Octaplas, spontaneous generation of C3
fragments was completely restored and to a much higher
level than that observed in normal humans (Fig. 3 B). The
levels of C3 and C4 were not significantly increased in the
patient’s plasma after the Octaplas infusion, and the addi-
tion of Octaplas to plasma from normal humans in vitro did
not enhance the level of spontaneous C3 fragment genera-
tion (data not shown).
Exogenous Ig Activates Complement and Generates C3 Frag-
ments in Plasma from RAG /  Mice. Plasma from RAG / 
mice was reconstituted with purified murine monoclonal
Ig in vitro to examine more closely the ability of specific Ig
isotypes to activate complement and generate C3 frag-
ments. Table II gives a complete list of the Igs tested and
shows a number of important points. First, each mono-
clonal Ig tested exhibited a highly reproducible ability to
activate C3 in RAG /  plasma. Second, the Fc portion of
IgG appeared to be required for C3 activation as, if this
Figure 2. Spontaneous formation of C3 fragments in mouse plasma re-
quires the classical complement pathway. The rate of formation of C3
fragments in heparin-containing plasma from C57BL/6 mice ( ), and
C1qa /  mice ( ) is depicted, as measured by the binding of C3 frag-
ments to B220  spleen cells using immunofluorescence flow cytometry, as
shown in Fig. 1 A. Error bars represent   SD of means of triplicate assays.
Table I. Spontaneous Formation of C3 Fragments in Mouse 
Plasma Requires the Classical Complement Pathway and Plasma Ig
In vitro incubation time
Mouse strain 5 min 10 min 15 min
Normal 100   6 100   5 100   2
Clqa /  1   11     02     1
C4 /  0   0 1    11     1
Bf /  30   4 22   14 54   26
H2-Bf,C2 /  4   40     00     0
RAG /  11   4 15   2 16   2
Heparinized blood from normal C57BL/6, complement component-
deficient, and Ig-deficient (RAG / ) mice was incubated for 5, 10, and
15 min ex vivo before the addition of EDTA. Plasma was then collected
from the blood samples and the level of C3 fragments generated
determined by immunofluorescence flow cytometry, as illustrated in
Fig. 1 A. Results are expressed as the percentage of C3 fragments present
compared with the level generated in blood from normal C57BL/6
mice. All results are presented as means    SD, and data are
representative of at least two separate experiments.752 Continual Activation of the Classical Complement Pathway
portion was removed from IgG1, it lost its ability to acti-
vate complement and generate C3 fragments in plasma.
Third, all of the monoclonal IgGs tested were able to acti-
vate complement although there was considerable variation
in activity both between isotypes and even within the iso-
types tested. For example, the two IgG2a  samples tested
were both able to activate complement very efficiently
compared with IgG2b. However, comparison between the
IgG2a  and IgG2a  samples tested showed a 10–20-fold
difference in the efficiency of complement activation and
generation of C3 fragments. This result not only shows
variation within the IgG2a isotype but also suggests that
light-chain type may have an effect on the efficiency of C3
activation. Finally, all three IgM samples tested were only
poor activators and one was unable to activate comple-
ment, suggesting that IgG probably plays a more important
role in this phenomenon than IgM.
All myeloma preparations were analyzed by fast perfor-
mance liquid chromatography (FPLC) to ensure that no Ig
aggregates were present before use, and some preparations
were also centrifuged (10 min, 20,000 g) to remove large
aggregates, a procedure that was shown to have little or no
effect on their ability to spontaneously activate comple-
ment (data not shown).
C3 Fragments Are Formed and Accumulate in Blood within
the Circulation in a Vascular Stasis Model. To test if C3
fragments are formed and accumulate in blood within the
circulation as observed in vitro, a model of vascular stasis
was established. Heparin was initially injected into mice to
prevent clotting of blood in the vasculature, and then the
mice were killed by CO2 administration. Such a procedure
effectively creates stasis of the blood within the vasculature
of the mice. At different time points after the death of the
mice blood was collected directly into EDTA (10 mM) to
prevent any further C3 fragments being generated ex vivo.
As shown in Fig. 4, C3 fragments were generated in the
blood of C57BL/6 mice within the circulation, beginning
to appear 15 min after CO2 administration and then rapidly
accumulating over the next 15 min, an effect that was not
observed in the blood of C1qa /  mice. Only low levels of
C3 fragments were detected in the blood of mice during
the first 15 min after CO2 administration (data not shown).
The reason for the apparent lag time in vivo before the for-
mation of the C3 fragments is unclear but may be due to a
Figure 3. Spontaneous formation of C3 fragments in human plasma is
C1q dependent. (A) Plasma from normal and C1q-deficient patients,
containing heparin and EDTA, was recalcified and incubated at 37 C for
up to 30 min. To some C1q-deficient plasma exogenous purified human
C1q (20  g/ml) was added before incubation. The rate of formation of
C3 fragments in normal ( , n   8), C1q-deficient ( , n = 3), and recon-
stituted C1q-deficient ( , n   3) plasma is depicted, as measured by the
binding of C3 fragments to Raji cells using immunofluorescence flow cy-
tometry, as in Fig. 1 C. (B) The rate of formation of C3 fragments in
plasma from normal individuals ( , n   8), and a C1q-deficient patient
before ( ) and immediately after ( ) infusion of Octaplas. All results are
represented as means   SD.
Table II. Ability of Different Mouse Igs to Induce C3 Fragment 
Generation in Plasma from RAG /  Mice
Mouse Ig
isotype Source Clone Specificity
Percent
increase
in C3
fragments
generated
IgG1 Hybridoma 8.7 Human CD32 69   22
F(ab) 2 IgG1 Hybridoma 8.7 Human CD32 5   5
IgG1 Myeloma MPOC-31c Unknown 78   13
IgG1 Hybridoma WV2 Human CD94 154   8
IgG1 Hybridoma R73 Rat  /  TCR 182   14
IgG1 Hybridoma HA58 Human CD54 388   32
IgG2a  Myeloma UPC-10  -2-6 fructosan 734   71
IgG2a  Hybridoma DX27 Human CD158b 315   18
IgG2a  Myeloma HOPC-1 Unknown 34   11
IgG2b Myeloma MOPC-141 Unknown 36   15
IgG3 Myeloma FLOPC-21 Unknown 170   8
IgM Myeloma TEPC 183 Unknown 0
IgM Hybridoma WV4 Human CD94 67   6
IgM Hybridoma WV5 Human CD56 82   6
IgM Hybridoma WV7 Human CD57 61   6
IgA Myeloma TEPC 15 Phosphoryl
choline
0
Heparinized blood from RAG /  mice was added to purified Igs (50
 g/ml) and incubated for 10 min ex vivo before the addition of 10 mM
EDTA. Plasma was then collected from the blood samples and the level
of C3 fragments generated determined by immunofluorescence flow
cytometry, as illustrated in Fig. 1 A. Results are expressed as percentage
increase in C3 fragments compared to normal heparinized RAG / 
plasma. Errors represent   SD of mean of triplicate assays, and data are
representative of at least two separate experiments.753 Manderson et al.
corresponding lag time in the induction of complete blood
stasis and inactivation/saturation of clearance mechanisms.
Table III summarizes the rate of formation of C3 fragments
generated within the circulation in normal, complement
component–deficient, and Ig-deficient mice after induction
of vascular stasis, and shows parallel findings to those ob-
served in plasma from these mice using the in vitro model
(Table I). Spontaneous complement activation within the
circulation was totally dependent on the classical comple-
ment pathway components C1q, C4, and C2, highly de-
pendent on Ig, and partially dependent on the alternative
complement pathway.
Elevated C3 and C4 Levels in Mice and Humans with Com-
plement Deficiencies. C3 has been shown to be continually
consumed by the alternative complement pathway due to a
low level of spontaneous hydrolysis of the native C3 mole-
cule (1, 2) that initiates formation of the alternative path-
way C3 convertase. Consistent with this phenomenon,
mice deficient in the alternative complement pathway
(Bf / ) had elevated levels of plasma C3 in comparison
with wild-type C57BL/6 mice (Fig. 5 A, P   0.0001).
Surprisingly, elevated plasma C3 levels were also detected
in mice deficient in C1q (C1qa / ) and plasma Ig (RAG / )
compared with normal C57BL/6 mice (Fig. 5 A, P =
0.001, P   0.0001, respectively). The highest levels of
plasma C3 were detected when mice were deficient in
both the classical and alternative complement pathways
(H2-Bf,C2 / ) in comparison with mice deficient in C1q
(P   0.0001) or factor B alone (P   0.0001). Although the
absence of Ig in the RAG /  mice may explain the ele-
vated C3 levels in these mice, it is also possible that other
factors, including underlying infections, may also contrib-
ute to the raised C3 levels.
In humans, plasma C3 levels were not elevated in C1q-
deficient patients (median 0.91, range 0.84–1.34 g/liter)
compared with normal individuals (median 0.97, range
0.84–1.27 g/liter), but plasma C4 levels were significantly
elevated (P   0.008) in the C1q-deficient patients (median
0.48, range 0.45–0.52 g/liter) compared with normal indi-
viduals (median 0.28, range 0.16–0.35 g/liter), consistent
with previously published data (27, 28).
Discussion
Activation of complement can occur via three pathways:
the alternative, mannose-binding lectin, and classical. The
alternative pathway has been shown to be continually un-
dergoing a low level of spontaneous activation (1), whereas
Figure 4. Formation of C3 fragments in mouse blood in vivo after vas-
cular stasis requires the classical complement pathway. After injection of
heparin (20 U) mice were killed by CO2 exposure, blood was collected
from the mice at appropriate times after death of the mice, and the plasma
analyzed for C3 fragments by immunofluorescence flow cytometry, as
shown in Fig. 1 A. The rate of C3 fragment formation was examined in
the plasma of C57BL/6 mice ( ) and C1qa /  mice ( ). Error bars rep-
resent   SD of mean of triplicate assays. Data are representative of two
separate experiments.
Table III. Formation of C3 Fragments in Blood after Vascular 
Stasis Requires the Classical Complement Pathway and Plasma Ig
Vascular stasis time
Mouse strain 15 min 30 min
Normal 100   22 100   11
Clqa /  5   24     2
C4 /  0   00     0
Bf /  46   33 19   2
H2-Bf,C2 /  0   00     0
RAG /  13   24     1
Blood was collected from normal C57BL/6, complement component–
deficient, and Ig-deficient (RAG / ) mice, as in Fig. 4, and the level of
C3 fragments generated 15 and 30 min after death determined by
immunofluorescence flow cytometry, as illustrated in Fig. 1 A. Results
are expressed as the percentage of C3 fragments present compared with
the level generated in blood from normal C57BL/6 mice. All results are
presented as means   SD, and data are representative of at least two
separate experiments.
Figure 5. Elevated plasma C3 levels in mice deficient in molecules es-
sential for activation of both the classical and alternative complement
pathways. Blood was collected from mice directly into EDTA and the
level of plasma C3 determined by rocket immunoelectrophoresis. The
plasma C3 levels from individual male C57BL/6 ( , n   14), Bf /  ( ,
n   20), C1qa /  ( , n = 12), H2-Bf,C2 /  ( , n   9), and RAG / 
( , n   12) mice is depicted, with horizontal bars denoting means. Simi-
lar trends in C3 levels were observed in female mice (data not shown).754 Continual Activation of the Classical Complement Pathway
the classical and lectin pathways have been thought to re-
quire specific pathogen recognition for activation (29).
Lachmann and colleagues first hypothesized that, analogous
to the “C3-tickover” of the alternative pathway, the classi-
cal pathway may also be activated via a C1-tickover mech-
anism (30). When they added oxidized C2, a form that
allows the stable formation of the classical pathway C3
convertase C4oxyC2, to normal human serum spontaneous
cleavage of C3 was observed. Our findings confirm the ex-
istence of this pathway and show that C3 is continually ac-
tivated through the classical complement pathway in the
plasma of mice and humans.
Our initial observations demonstrated that, immediately
after isolation of blood from mice and humans, C3d frag-
ments accumulated to high levels (Fig. 1). Complement ac-
tivation and formation of C3 fragments occurred via the
classical pathway, as shown in Fig. 2 and Table I, with no
spontaneous C3 fragment generation in plasma deficient in
C1q (C1qa /   mice), C4 (C4 /   mice), or plasma Ig
(RAG /  mice). Furthermore, addition of exogenous Ig to
the plasma from RAG /  mice restored spontaneous com-
plement activation and the generation of C3 fragments to
similar levels to those found in the plasma of normal
C57BL/6 mice (Table II), demonstrating the crucial role of
Ig and the classical complement pathway in C3 fragment
generation. Although the initial activation of complement
occurred through the classical pathway, the alternative
pathway was also required as isolated deficiency in factor B
(Bf /  mice) was associated with a decrease in the genera-
tion of C3 fragments (Table I). Presumably, C3 fragments
generated through spontaneous activation of the classical
pathway act to initiate alternative pathway C3 convertase
formation, resulting in additional C3 consumption.
In humans, spontaneous complement activation and for-
mation of C3 fragments also occurred via the classical path-
way, as shown in Fig. 3 A by the absence of C3 fragment
generation in plasma from C1q-deficient patients. The ab-
sence of spontaneous complement activation was solely due
to a classical pathway deficiency as reconstitution of plasma
from C1q-deficient patients, both in vitro by addition of
purified C1q and in vivo by the infusion of Octaplas, was
sufficient to restore the spontaneous generation of C3 frag-
ments to levels above those observed in plasma from nor-
mal individuals (Fig. 3 B). The higher level of spontaneous
complement activation observed, in comparison to normal
donors, could have two explanations. The first is due to the
increased levels of complement proteins in the pathway
downstream to the deficient protein, allowing greater com-
plement activation on restoration of the missing protein.
The second explanation is that there may be elevated levels
of circulating IC in the C1q-deficient individuals caused by
abnormalities of IC processing known to occur in patients
with hypocomplementaemia (31).
It should be noted that, due to the use of heparin as the
anticoagulant in this study, the rate of spontaneous C3 frag-
ment generation in mice, but not in humans, may have
been underestimated, as demonstrated by the enhanced
levels of C3 fragments generated in mouse plasma in the
presence of hirudin. Such a result is not surprising as hep-
arin is known to be anticomplementary (32–35).
In addition to observing the spontaneous formation of
C3 fragments in plasma directly ex vivo, the fragments also
formed within the circulation (Fig. 4, Table III). C3 frag-
ments rapidly accumulated to high levels in the blood of
C57BL/6 mice killed by CO2 administration (Fig. 4) after
an initial 15-min lag phase, which presumably was required
for establishment of complete blood stasis and inactivation/
saturation of clearance mechanisms for C3 fragments. This
activation of complement was also dependent on the classi-
cal pathway and the presence of Ig, with the alternative
pathway being required for normal levels of spontaneous
C3 fragment generation (Table III), as observed in the ex
vivo situation.
C3 is continually consumed through the “tick-over” ac-
tivation of the alternative complement pathway (1, 2),
therefore the absence of this pathway in factor B–deficient
mice (Bf / ) accounts for the elevated plasma C3 levels de-
tected in these mice (Fig. 5). The observation that C1qa / 
and Ig-deficient (RAG / ) mice also had elevated plasma
C3 levels (Fig. 5) suggests that under normal conditions C3
is additionally being consumed through the classical path-
way, a hypothesis consistent with the in vitro and in vivo
data. In addition, even higher levels of plasma C3 were de-
tected in mice deficient in both the classical and alternative
pathways (H2-Bf,C2 /  mice) suggesting independent
mechanisms of C3 consumption through the two activa-
tion pathways.
In humans, activation of complement in blood ex vivo is
thought, at least in part, to be a consequence of comple-
ment activation by natural cold-reacting autoantibodies
(agglutinins) (36, 37). However, the presence of cold ag-
glutinins in blood is unable to explain the complement ac-
tivation observed in our system. In the ex vivo assay em-
ployed the human and mouse blood was incubated at 37 C
immediately after collection and at no stage, before the ad-
dition of EDTA, was it cooled to allow the autoantibodies
to bind to erythrocytes and activate complement. In addi-
tion, most cold agglutinins characterized are of the IgM
isotype, but IgG rather than IgM appears to be the domi-
nant Ig isotype that induced spontaneous complement acti-
vation in these experiments.
It has previously been reported that in mice the classical
complement pathway is activated most effectively by IgM
after binding of antigen, with IgG2a, IgG2b, and IgG3 also
being good activators, whereas IgG1 is a very poor activa-
tor of complement (10, 11). An intriguing aspect of this
study is that there was a discrepancy between the ability of
the different Ig isotypes to spontaneously activate C3 frag-
ment generation, and their known ability to activate the
classical complement pathway after antigen binding. For
example, based on RAG /  plasma reconstitution experi-
ments (Table II), IgG appears to be a better spontaneous
activator of complement than IgM. In addition, IgG1 anti-
bodies induced spontaneous activation of complement, an
isotype believed to be a poor activator of complement via
the classical pathway. The explanations for these findings is755 Manderson et al.
not known. Possibly, secondary mediators may be involved
that bind to and regulate the ability of antibodies to sponta-
neously activate complement. A potential candidate protein
is histidine-rich glycoprotein (HRG) which has been
shown to bind to the hinge region of some Igs, particularly
IgGs, and also to bind C1q (38). Interestingly, the light-
chain type (  or  ) of an antibody also affected its ability to
spontaneously activate complement (Table II), and the af-
finity of HRG for IgG is also dramatically affected by
whether the IgG contains   or   light chains (39).
In addition to isotype variation, individual mAbs of each
isotype varied considerably in their ability to spontaneously
activate complement. This point was most evident in com-
parisons between different IgG1 and IgG2a mAbs (Table
II) which ranged from the poorest through to the best
spontaneous activators of C3 fragment formation. As anti-
bodies of the same isotype only differ from each other in
two aspects, namely the antigen-specific variable region
and the level and type of glycosylation, these properties
must either individually or in combination account for the
observed variations. Neuberger and Rajewsky (11) also ob-
served some differences between individual monoclonal
IgG2 and IgM antibodies in their ability to fix complement
and could partially explain this discrepancy as being due to
the variable region and thus the affinity of the antibodies
for specific antigen, in this case NP (4-hydroxy-3-nitro-
phenyl)acetyl. In our system it is possible that the antibod-
ies tested were recognizing self-antigens in plasma, and that
variations in the affinity of the different mAbs for specific
plasma autoantigens may account for some of the variations
in the observed ability of the antibodies to spontaneously
activate complement.
Two possible mechanisms could account for the sponta-
neous complement activation induced by plasma Ig. First, a
continual low level of circulating IC may be present in
plasma. This is consistent with the observation that plasma
from C1q-deficient patients, that is known to contain high
levels of circulating IC, exhibited much higher levels of
spontaneous complement activation than normal individu-
als when reconstituted with C1q. However, as discussed
earlier, the ability of different Ig isotypes to spontaneously
activate complement varies from their known ability to ac-
tivate the classical complement pathway when bound
within IC. Thus, an alternative explanation is that Ig-depen-
dent complement activation may occur in plasma in the ab-
sence of specific antigen, via the continual spontaneous for-
mation of unstable Ig aggregates, a process enhanced by
linker proteins like HRG. Such a view is supported by the
fact that Fc–Fc interactions have been shown to spontane-
ously occur between IgG molecules in IC (40) and the well
known ability of the Fc portion of Ig to aggregate and form
crystals (41). This aggregation may be encouraged or initi-
ated by vascular stasis. Complement activation would
therefore be augmented at sites of inflammation at which
there may be thrombosis and vascular stasis, leading to Ig
aggregate formation, providing a favorable environment for
the activation of complement.
In conclusion, these findings indicate that C3 is consumed
through the spontaneous activation of the classical comple-
ment pathway. This may represent an analogous mechanism
to the continual tick-over of C3 via the alternative comple-
ment pathway. It may facilitate pathogen recognition by al-
lowing the deposition of activated C3 fragments on foreign
surfaces at sites of vascular stasis (1–4). An important corol-
lary of this mechanism for spontaneous activation of the
classical pathway, however, is that C3 fragments might ac-
cumulate after vascular stasis. This could contribute deleteri-
ously to tissue injury in tissue infarction in which comple-
ment has been shown to play an important role (42, 43).
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